AVTE vs. LBPH, BCYC, YMAB, PHAR, ORIC, SLN, SIGA, ZYME, PRTC, and PRAX
Should you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Longboard Pharmaceuticals (LBPH), Bicycle Therapeutics (BCYC), Y-mAbs Therapeutics (YMAB), Pharming Group (PHAR), ORIC Pharmaceuticals (ORIC), Silence Therapeutics (SLN), SIGA Technologies (SIGA), Zymeworks (ZYME), PureTech Health (PRTC), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical preparations" industry.
Longboard Pharmaceuticals (NASDAQ:LBPH) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, community ranking, dividends, earnings, institutional ownership and analyst recommendations.
Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Longboard Pharmaceuticals presently has a consensus price target of $39.50, suggesting a potential upside of 111.57%. Aerovate Therapeutics has a consensus price target of $49.33, suggesting a potential upside of 122.52%. Given Longboard Pharmaceuticals' higher possible upside, analysts plainly believe Aerovate Therapeutics is more favorable than Longboard Pharmaceuticals.
Longboard Pharmaceuticals' return on equity of -61.62% beat Aerovate Therapeutics' return on equity.
Longboard Pharmaceuticals received 24 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 71.43% of users gave Longboard Pharmaceuticals an outperform vote while only 64.00% of users gave Aerovate Therapeutics an outperform vote.
In the previous week, Aerovate Therapeutics had 5 more articles in the media than Longboard Pharmaceuticals. MarketBeat recorded 10 mentions for Aerovate Therapeutics and 5 mentions for Longboard Pharmaceuticals. Aerovate Therapeutics' average media sentiment score of 0.60 beat Longboard Pharmaceuticals' score of 0.60 indicating that Longboard Pharmaceuticals is being referred to more favorably in the media.
Longboard Pharmaceuticals has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.
63.3% of Longboard Pharmaceuticals shares are held by institutional investors. 4.6% of Longboard Pharmaceuticals shares are held by company insiders. Comparatively, 19.3% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Longboard Pharmaceuticals beats Aerovate Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Aerovate Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aerovate Therapeutics Competitors List
Related Companies and Tools
